First Results from a Phase 1, First-in-Human Study of the Bruton's Tyrosine Kinase (BTK) Degrader Bgb-16673 in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Malignancies (BGB-16673-101)

布鲁顿酪氨酸激酶 伊布替尼 慢性淋巴细胞白血病 套细胞淋巴瘤 医学 滤泡性淋巴瘤 华登氏巨球蛋白血症 肿瘤溶解综合征 中性粒细胞减少症 癌症研究 放射免疫疗法 内科学 淋巴瘤 免疫学 白血病 酪氨酸激酶 毒性 化疗 抗体 受体 单克隆抗体
作者
John F. Seymour,Chan Y. Cheah,Ricardo Parrondo,Meghan C. Thompson,Don A. Stevens,Masa Lasica,Michael L. Wang,Abhijeet Kumar,Judith Trotman,Maan Alwan,Wei Ding,Kunthel By,Bilal Tariq,Xiangmei Chen,Shannon Fabre,Jason C. Paik,Amit Kumar Agarwal,Constantine S. Tam
出处
期刊:Blood [Elsevier BV]
卷期号:142 (Supplement 1): 4401-4401 被引量:7
标识
DOI:10.1182/blood-2023-180109
摘要

Introduction: BTK inhibitors (BTKis) are approved for chronic lymphocytic leukemia (CLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), and marginal zone lymphoma (MZL). Disease that progresses on BTKis often has BTK mutations that lead to treatment (tx) resistance; novel BTK-targeting agents that overcome BTKi resistance are needed. BGB-16673 is a heterobifunctional small molecule that binds to BTK and E3 ligase, resulting in BTK degradation via ubiquitination. In preclinical models, BGB-16673 degraded wild-type (WT) BTK and known covalent and noncovalent BTKi-resistant mutant proteins, leading to tumor suppression. Methods: Pts with R/R CLL, WM, MCL, MZL, non-germinal center B-cell diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), or Richter transformation (RT) were eligible for this open-label, first-in-human, phase 1 trial (BGB-16673-101; NCT05006716). Pts must have received ≥2 prior therapies (≥1 for RT) and have an ECOG performance status of 0-2 and adequate end-organ function. In the US and Australia, pts must have received a covalent BTKi (cBTKi) if approved for their disease. BGB-16673 was dosed daily by mouth in 28-day cycles. Escalation using a Bayesian optimal interval design with 6 dose levels (50-600 mg once daily) is planned. Primary objectives are to assess safety/tolerability and establish the maximum tolerated dose (MTD) and recommended phase 2 dose. Key secondary objectives are to assess pharmacokinetics, pharmacodynamics (PD), and preliminary antitumor activity. Safety was assessed according to CTCAE v5.0 (all pts) and iwCLL hematologic toxicity criteria (pts with CLL). Dose-limiting toxicities (DLTs) were assessed in the first 4 weeks. Response was assessed per Lugano criteria for all except CLL (iwCLL 2018 criteria) and WM (iwWM-6 criteria). Results: As of May 26, 2023, 26 pts (10 CLL, 4 MCL, 2 MZL, 4 WM, 4 FL, 1 DLBCL, 1 RT) were enrolled at 5 dose levels (50 mg, 4; 100 mg, 9; 200 mg, 9; 350 mg, 3; 500 mg, 1). Median age was 70.5 y (range, 25-83). Median number of prior therapies was 3.5 (range, 2-9), including cBTKis (n=21; 10 CLL, 4 WM, 4 MCL, 1 MZL, 1 RT, 1 DLBCL), BCL2 inhibitors (n=12; 9 CLL, 2 WM, 1 RT), and noncovalent BTKis (ncBTKis; n=4; 2 CLL, 1 WM, 1 FL). In CLL, del17p/ TP53 mutation (n=8) and unmutated IGHV (n=7) were frequent. Median follow-up was 3.5 mo (range, 0.2-13.9). MTD was not reached. Treatment-emergent AEs (TEAEs) were reported by 88.5% of pts (grade [gr] ≥3, 46.2%; serious, 38.5%). The most common TEAEs were contusion (30.8%; no gr ≥3), pyrexia (23.1%; no gr ≥3), neutropenia/neutrophil count decreased (23.1%; gr ≥3, 15.4%), and lipase increased (23.1%; gr ≥3, 3.8%; all transient and asymptomatic). No hypertension or atrial fibrillation was observed. One pt died from sepsis with possible disease progression. No discontinuations due to AEs occurred. Two pts had dose reductions due to TEAEs (gr 3 hematuria with urinary tract infection and recurrent urothelial carcinoma and gr 2 arthralgia). One DLT occurred in 1 pt at 200 mg (gr 3 maculopapular rash on day 27; after 5-day dose hold, assigned dose was recommenced with persistent gr 1 rash). BGB-16673 exposure increased in a dose-dependent manner. At steady state with doses ≥50 mg daily, BGB-16673 exposure exceeded the calculated half maximal degradation concentration for WT and cysteine 481-mutated BTK for the dosing interval. Preliminary PD data showed deep, sustained reductions in BTK protein levels in peripheral blood and tumor tissue, even at the lowest dose. Most CLL pts experienced lymphocytosis during the first 3 cycles of tx. Twenty of 26 pts (77%) remain on therapy (discontinuation: 4 progressive disease, 2 withdrawal). Of 18 response-evaluable pts, 12 (67%) responded (5/6 CLL, 1/3 MCL, 2/2 MZL, 3/4 WM, 1/2 FL, 0/1 DLBCL; 1 CR in MCL, all others had PR; Figure), including pts who received a cBTKi (n=10) and an ncBTKi (n=2). Responses started at the lowest dose level. All responders remain in response, the longest responder remaining on tx for 60 weeks. Conclusions: Preliminary data from this ongoing, first-in-human study of the novel BTK degrader BGB-16673 demonstrate a tolerable safety profile and clinical responses in heavily pretreated pts with B-cell malignancies, including those with BTKi-resistant disease. Substantial reductions in BTK protein levels in peripheral blood and tumor tissue were also observed, demonstrating proof-of-concept of a strong, on-target effect.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
5秒前
7秒前
学习使勇哥进步完成签到 ,获得积分10
9秒前
DE2022发布了新的文献求助10
12秒前
风清扬应助bai采纳,获得20
13秒前
16秒前
秋夜临完成签到,获得积分0
22秒前
昔昔完成签到 ,获得积分10
23秒前
DE2022完成签到,获得积分10
26秒前
量子星尘发布了新的文献求助10
28秒前
yangxiaoxu完成签到 ,获得积分10
28秒前
hhh2018687完成签到,获得积分10
36秒前
蒲蒲完成签到 ,获得积分10
37秒前
喜悦向日葵完成签到 ,获得积分10
38秒前
思绪摸摸头完成签到 ,获得积分10
40秒前
缥缈的闭月完成签到,获得积分10
43秒前
科研狗的春天完成签到 ,获得积分10
43秒前
和谐的夏岚完成签到 ,获得积分10
44秒前
zhilianghui0807完成签到 ,获得积分10
45秒前
51秒前
zhixin完成签到,获得积分10
52秒前
bckl888完成签到,获得积分10
53秒前
倒立的松鼠完成签到 ,获得积分10
54秒前
王佳豪完成签到,获得积分10
58秒前
忽晚完成签到 ,获得积分10
1分钟前
yunt完成签到 ,获得积分10
1分钟前
玉yu完成签到 ,获得积分10
1分钟前
画月完成签到 ,获得积分10
1分钟前
量子星尘发布了新的文献求助10
1分钟前
wxz完成签到,获得积分10
1分钟前
1分钟前
1分钟前
千玺的小粉丝儿完成签到,获得积分10
1分钟前
又又完成签到,获得积分10
1分钟前
1分钟前
笨笨忘幽完成签到,获得积分10
1分钟前
CLTTT完成签到,获得积分10
1分钟前
Tong完成签到,获得积分0
1分钟前
诺亚方舟哇哈哈完成签到 ,获得积分0
1分钟前
墨瞳完成签到,获得积分10
1分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976735
求助须知:如何正确求助?哪些是违规求助? 3520831
关于积分的说明 11204855
捐赠科研通 3257602
什么是DOI,文献DOI怎么找? 1798814
邀请新用户注册赠送积分活动 877897
科研通“疑难数据库(出版商)”最低求助积分说明 806663